Blog | HemaCare

Researchers are Closer to Entirely Eliminating HIV Reservoirs from Patients

Dec 7, 2015 1:00:38 PM / by Karina Palomares posted in HIV latency, Cytotoxic T Cells, HIV, research


Dual-Affinity Re-Targeting (DART) molecules incorporating Env-binding specificities with a CD3-binding specificity potently and selectively kill HIV-infected cells.

We recently discussed how new research indicates that activation of latent HIV is a necessary step for eradication of disease. Most antiretroviral drugs only target actively replicating HIV. If antiretroviral therapy is stopped, latent HIV returns to an active form, resulting in a rebound of viral load. Thus, activation of latent HIV to render it susceptible to antiretroviral drugs is a potential strategy to completely eliminate HIV reservoirs.

Read More

Skin Cancer Drug Flushes Out HIV Reservoirs

Oct 19, 2015 1:00:30 PM / by Karina Palomares posted in HIV latency, research, skin cancer


PEP005, an active component in an FDA-approved drug for the topical treatment of precancerous skin lesions, can effectively reactivate latent HIV with relatively low cellular toxicity.

The treatment of HIV and AIDS has changed considerably over the last few decades with the development of antiretroviral therapy (ART). In most patients treated with ART, plasma virus levels decrease to undetectable levels, disease progression stops, and reconstitution of the immune system begins. However, if a patient stops therapy, latent HIV reservoirs are reignited. Thus, new strategies that reactivate and eliminate latent virus are necessary to completely eradicate the disease.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts